HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Intravitreal bevacizumab (avastin) combined with vitrectomy for recurrences of proliferative vitreoretinopathy in Von Hippel-Lindau disease.

AuthorsRyotaro Tano, Keigo Kakurai, Toshiya Sakurai, Ritsuko Fujiwara, Tomiya Mano, Takatoshi Maeno
JournalActa ophthalmologica (Acta Ophthalmol) Vol. 90 Issue 2 Pg. e157-8 (Mar 2012) ISSN: 1755-3768 [Electronic] England
PMID21649868 (Publication Type: Case Reports, Letter)
Chemical References
  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal, Humanized
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • Bevacizumab
Topics
  • Adult
  • Angiogenesis Inhibitors (therapeutic use)
  • Antibodies, Monoclonal, Humanized (therapeutic use)
  • Bevacizumab
  • Combined Modality Therapy
  • Female
  • Humans
  • Intravitreal Injections
  • Male
  • Recurrence
  • Treatment Outcome
  • Vascular Endothelial Growth Factor A (antagonists & inhibitors)
  • Vitrectomy
  • Vitreoretinopathy, Proliferative (diagnosis, etiology, therapy)
  • von Hippel-Lindau Disease (complications, diagnosis)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: